How Far You Can Walk

Peripheral artery disease narrows the arteries in the legs, and its defining symptom is having to stop walking because of pain. Almost nothing improves it. A trial of 792 people measured the thing that matters — how far they could actually walk — and semaglutide beat placebo by 13%.^[1] Then look at the spread, because a quarter of the people on the drug walked less far than when they started.

Why this endpoint is different

Most of what we cover on this register is a number from a blood test or a scan, standing in for something a person would notice. This is not that. Participants walked on a treadmill at a fixed workload until leg pain stopped them, at the start and again a year later. The endpoint is the distance.

Peripheral artery disease affects an estimated 230 million people, and the treatments that improve how far someone can walk are few. That is why a functional result here is worth more than a laboratory one.

Two things the headline number hides

The first is that the placebo group improved too, by 8%. Repeated treadmill testing has a learning effect, and being in a trial changes how much people walk between visits. So the drug’s own contribution is the 13% difference, not the 21% improvement.

That is not a flaw in the trial — it is what progressive vascular disease looks like, and the placebo group’s lower quartile is worse still, at 0.86. But a median improving while a substantial minority declines is a different picture from “semaglutide improves walking distance,” and it is the picture someone deciding about treatment should have.

The middle of the group walked further. A quarter of them walked less.

Safety, and what the trial did not ask

Treatment-related serious adverse events were uncommon and slightly more frequent on placebo — six events in five participants on semaglutide against nine in six on placebo. There were no treatment-related deaths. For a 52-week trial in people with a median age of 68 and established vascular disease, that is a reassuring safety picture.

• The dose was 1.0 mg — the type 2 diabetes strength, not the 2.4 mg used for weight management.
• Everyone had type 2 diabetes. The authors explicitly call for studies in people with peripheral artery disease who do not, which is a large group.
• Three-quarters were men, and the median age was 68.
• Nothing here addresses amputation, revascularization or survival — the outcomes that define how this disease ends.
• Funded by Novo Nordisk.

The authors also note that the mechanism is unclear. Whether the benefit comes from weight loss, from improved blood sugar, from effects on the blood vessels themselves, or from something else is unresolved — and the broader pattern we have documented is that these drugs’ vascular benefits do not track weight loss.

What it means for someone with claudication

Trial participants had to be able to walk more than 200 meters to enroll — Fontaine stage IIa, the milder end of symptomatic disease. Someone whose walking is more limited than that was not studied.

Within that group, this is genuine evidence for a functional benefit in a condition that has very little. It is a modest benefit, it is not universal, and it sits alongside supervised exercise therapy, which remains the best-established treatment for claudication and was not what this trial compared against.